BiomX (PHGE) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
8 Jun, 2026Executive summary
Annual Meeting scheduled for June 26, 2026, to be held virtually; record date is June 2, 2026.
Three proposals up for vote: election of one director, amendment to the 2026 Equity Incentive Plan, and adjournment if needed.
Board unanimously recommends voting FOR all proposals.
Proxy materials and annual report are available online; shareholders can vote by mail, phone, internet, or during the meeting.
Voting matters and shareholder proposals
Proposal 1: Elect Ran Shaked as Class III director for a term ending 2029.
Proposal 2: Approve amendment to increase shares reserved under the 2026 Equity Incentive Plan from 1,390,000 to 6,850,000.
Proposal 3: Approve adjournment of the meeting if more time is needed to solicit proxies.
Board recommends FOR all proposals; plurality required for director, majority for other proposals.
Board of directors and corporate governance
Board consists of four members; three are independent under NYSE American standards.
Committees: Audit (Liat Bidas, Chair), Compensation (Ran Shaked, Chair), Nominating and Corporate Governance (Liat Bidas, Chair).
Board held 22 meetings in 2025; all directors attended at least 75% of meetings.
No Chairman or lead independent director currently appointed.
Latest events from BiomX
- Q1 2026 net loss was $19.1M amid a strategic pivot to defense and security tech.PHGE
Q1 202620 May 2026 - Vote sought on a new equity plan with evergreen increases and recent leadership changes disclosed.PHGE
Proxy filing25 Mar 2026 - Approval granted for issuance of shares tied to Series Y preferred stock and warrants.PHGE
EGM 202611 Mar 2026 - Meeting adjourned and rescheduled due to lack of quorum; voting instructions remain valid.PHGE
EGM 202625 Feb 2026 - 2025 net loss reached $36.2M; cash burn and insolvency drive urgent need for new financing.PHGE
Q4 202519 Feb 2026 - Approval sought for major share issuance and potential meeting adjournment to secure votes.PHGE
Proxy Filing13 Feb 2026 - Registering 5.3M shares for resale may cause major dilution as focus shifts to phage therapies.PHGE
Registration Filing9 Feb 2026 - Approval sought for major stock issuance tied to recent $3M Private Placement and governance changes.PHGE
Proxy Filing3 Feb 2026 - $50M financing boosts pipeline, but losses and delisting risk require new capital by late 2025.PHGE
Q2 20241 Feb 2026